A month following Novartis’ foray into the paroxysmal nocturnal hemoglobinuria (PNH) treatment domain, AstraZeneca strengthens its position in this field as its latest contender, Voydeya, secures a groundbreaking approval in Japan. Voydeya (danicopan), an innovative oral factor D inhibitor, has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its application in combination with a C5 inhibitor to address PNH patients who have not responded adequately to C5 inhibitors.
Paroxysmal nocturnal hemoglobinuria is a rare and serious blood disorder characterized by the breakdown of red blood cells within blood vessels, a condition k...